| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to the creation of the Alzheimer's Research Collaborative |
|
|
of Texas. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Subchapter D, Chapter 102, Health and Safety |
|
|
Code, is amended by adding Section 102.157 to read as follows: |
|
|
Sec. 102.157. OVERSIGHT COMMITTEE FOR NEURODEGENERATIVE |
|
|
DISEASES. (a) In this section: |
|
|
(1) "Committee" means the Oversight Committee for |
|
|
Neurodegenerative Diseases. |
|
|
(2) "Nationally designated" means a designation from |
|
|
the National Institute on Aging. |
|
|
(3) "Research collaborative" means the Alzheimer's |
|
|
Research Collaborative of Texas. |
|
|
(b) The Oversight Committee for Neurodegenerative Diseases |
|
|
is the governing body of the Alzheimer's Research Collaborative of |
|
|
Texas. The committee is composed of the following eight members: |
|
|
(1) four members appointed by the lieutenant governor; |
|
|
and |
|
|
(2) four members appointed by the speaker of the house |
|
|
of representatives. |
|
|
(c) In making appointments to the committee, the lieutenant |
|
|
governor and the speaker of the house of representatives must each |
|
|
appoint: |
|
|
(1) three members who are physicians or scientists |
|
|
with extensive experience in the field of Alzheimer's disease and |
|
|
neurology; and |
|
|
(2) one member of the public. |
|
|
(d) From each group of appointees under Subsection (c)(1), |
|
|
one appointee must represent a nationally designated Alzheimer's |
|
|
Disease Research Center and shall serve as co-chair of the |
|
|
committee. |
|
|
(e) A member of the committee serves at the will of the |
|
|
official who appointed the member. |
|
|
(f) The research collaborative is established to support |
|
|
Alzheimer's disease research described by Subsection (h). The |
|
|
committee shall oversee the review processes and related procedures |
|
|
of the collaborative. |
|
|
(g) The committee shall establish standards and hire |
|
|
personnel as necessary to ensure the proper use of funds authorized |
|
|
for Alzheimer's disease research, facilities development, and |
|
|
caregiver resources consistent with the powers and duties described |
|
|
under Section 102.051. |
|
|
(h) The committee shall establish criteria for the research |
|
|
collaborative to support institutions of learning and advanced |
|
|
medical research facilities and collaborations in this state in all |
|
|
stages of finding the causes of Alzheimer's disease and other |
|
|
neurodegenerative diseases in humans and developing cures, from |
|
|
laboratory research to clinical trials, including programs to |
|
|
address the problem of access to advanced treatment for Alzheimer's |
|
|
disease. |
|
|
(i) The committee shall establish criteria for prioritizing |
|
|
its review of applications for grants to: |
|
|
(1) academic medical centers; |
|
|
(2) medical research facilities; and |
|
|
(3) collaborations with a nationally designated |
|
|
Alzheimer's Disease Research Center. |
|
|
SECTION 2. This Act takes effect September 1, 2023. |